ANDA 40760, held by Hikma. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 40760 (Hydroxychloroquine Sulfate), held by Hikma, was first approved by FDA on Aug 15, 2007, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Discontinued |
| Mar 21, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 21, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 18, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 20, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 28, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 1, 2020 | Supplement 6Labeling · Standard review | Approved | |
| Aug 15, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters